Haisco Pharmaceutical Group Co., Ltd.
002653
Classifica tra le azioni
#2011
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Prezzo delle azioni
$9.03
Capitalizzazione di mercato
$10.30B
Variazione (1 giorno)
4.55%
Variazione (1 anno)
24.15%
Paese
CN
Scambia Haisco Pharmaceutical Group Co., Ltd. (002653)
Categoria
Healthcare
Ricavi di Haisco Pharmaceutical Group Co., Ltd. (002653)
Ricavi nel Jun 2026 TTM: $794.50M
Secondo gli ultimi rapporti finanziari di Haisco Pharmaceutical Group Co., Ltd., i ricavi attuali dell'azienda (TTM) sono pari a $794.50M. Nel 2023, l'azienda ha registrato ricavi di $473.97M un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $437.13M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Haisco Pharmaceutical Group Co., Ltd. da 2008 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $794.50M | 55.83% |
| 2024 | $509.84M | 7.57% |
| 2023 | $473.97M | 8.43% |
| 2022 | $437.13M | 0.18% |
| 2021 | $436.34M | -14.39% |
| 2020 | $509.68M | -9.86% |
| 2019 | $565.44M | 13.51% |
| 2018 | $498.16M | 74.62% |
| 2017 | $285.29M | 37.97% |
| 2016 | $206.77M | 10.75% |
| 2015 | $186.71M | -4.47% |
| 2014 | $195.45M | 19.47% |
| 2013 | $163.60M | 27.19% |
| 2012 | $128.62M | 34.15% |
| 2011 | $95.88M | 8.81% |
| 2010 | $88.11M | 24.14% |
| 2009 | $70.98M | 36.50% |
| 2008 | $52.00M | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 1,488.97% |
US
|
|
| $2.23B | 180.43% |
US
|
|
| $15.74B | 1,881.68% |
AU
|
|
| $6.02B | 657.88% |
NL
|
|
| - | - |
CH
|
